SCC - Squamous Cell Carcinoma of Skin

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

InflaRx
InflaRxJENA, Germany
1 program
1
VilobelimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04812535Terminated30Est. Jun 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
InflaRxVilobelimab

Clinical Trials (1)

Total enrollment: 30 patients across 1 trials

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Start: Mar 2021Est. completion: Jun 202430 patients
Phase 2Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space